Johns Hopkins study suggests the commonly prescribed anti-retroviral drug efavirenz attacks brain cells
September 29, 2012
October 2, 2012

Novel Cell and Gene Therapies for HIV

Although the development of cell-based and gene transfer therapies has been slow, progress in a number of areas is evident. Advances in the fields of gene-targeting strategies, T-cell-based approaches, and HSCs have been encouraging, and a series of ongoing and planned trials to establish proof of concept for strategies that could lead to successful cell and gene therapies for HIV are under way. The eventual goal of these studies is to eliminate latent viral reservoirs and the need for lifelong antiretroviral therapy.

Nelson Vergel
Nelson Vergel
Chemical engineer, 34+ year HIV and cancer survivor, health author and educator . Founder of , , and

Comments are closed.